A new rule by the Trump administration may make it more challenging for women to access contraceptive services, despite evidence of the benefits to women, families, and the nation as a whole.
11β-MNTDC is a modified testosterone with androgenic and progestational activity that is being developed as a potential male contraceptive.
A genetic variant may play a major role in why hormonal contraception fails in some women, according to a new study published in Obstetrics & Gynecology.
Apotex announced a voluntary recall of 4 lots of Drospirenone and Ethinyl Estradiol Tablets 3mg/0.03mg due to the possibility of defective blisters with incorrect tablet arrangements and/or empty blister pockets.
The Endocrine Society has objected the US Department of Health & Human Services’ update to the Title X Family Planning Program.
Researchers compared long-acting reversible contraceptive insertion rates in the 30 days before and after the 2016 presidential election.
Previous Phase 2 studies confirmed esterol has minimal impact on liver cells and metabolic pathways, as well as on coagulation parameters.
The U.S. Food and Drug Administration is implementing a number of steps for long-term safety monitoring of the permanent birth control device Essure, which will no longer be sold or distributed in the United States after Dec. 31, 2018.
Almost two-thirds of U.S. women aged 15 to 49 years were currently using contraception in 2015 to 2017.
Phase 3 trial results assessing the intrauterine system, Liletta (levonorgestrel 52 mg), found that it had >99% efficacy in preventing pregnancy for up to 5 years; the products current Food and Drug Administration indication.
